Previous 10 | Next 10 |
The following slide deck was published by United Therapeutics Corporation in conjunction with this Read more ...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , May 6, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Mr. James Edgemond , Chief Financial Officer and Treasurer of United Therapeutics, will provide an overview and update on the compa...
Image source: The Motley Fool. United Therapeutics Corp (NASDAQ: UTHR) Q1 2020 Earnings Call Apr 29, 2020 , 9:00 a.m. ET Operator Continue reading
United Therapeutics Corporation (UTHR) Q1 2020 Earnings Conference Call April 29, 2020, 9:00 am ET Company Participants Dewey Steadman - Head, IR Martine Rothblatt - Chairman & CEO Michael Benkowitz - President & COO Leigh Peterson - VP, Product Development James Edge...
United Therapeutics ( UTHR ) Q1 results : More news on: United Therapeutics Corporation, Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
United Therapeutics (NASDAQ: UTHR ): Q1 Non-GAAP EPS of $3.61 beats by $0.17 ; GAAP EPS of $3.12 beats by $0.50 . More news on: United Therapeutics Corporation, Earnings news and commentary, Healthcare stocks news, Read more ...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , April 29, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the quarter ended March 31, 2020 . First quarter net revenue decreased 2% to $356.3 million year-over-year whi...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , April 23, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today detailed recent publications on Orenitram ® (treprostinil) Extended-Release Tablets, which provide additional evidence of the beneficial t...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , April 22, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2020 financial results before the market opens on Wednesday, April 29, 2020 . United Therapeu...
WARREN, N.J. , April 9, 2020 /PRNewswire/ -- Celularity Inc. ("Celularity" or the "Company"), a clinical-stage company developing allogeneic cellular therapies from human placentas, today announced the expansion of its existing collaborative license agreement with United Therapeutics...
News, Short Squeeze, Breakout and More Instantly...
United Therapeutics Corporation Company Name:
UTHR Stock Symbol:
NASDAQ Market:
United Therapeutics Corporation Website:
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...
2024-07-11 06:30:06 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for UTHR on July 11, 2024 04:53AM ET. The previous analyst recommendation was Overweight. UTHR was trading at $329.25 at issue of the analyst recommendation. The overall analyst consensus : ...
Over 100,000 patients in the United States have IPF, with two approved therapies available that only slow the course of disease progression Top line data expected in the second half of 2025 United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announ...